Commitments and Contingencies

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 6. Commitments and Contingencies

Contingent Consideration

The Company recorded contingent consideration related to the 2019 acquisition of Enteris and sharing of certain milestone and royalties due to Enteris pursuant to the License Agreement. Contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in the estimated fair value recognized in earnings. The estimated fair value of contingent consideration as of September 30, 2022 and December 31, 2021 was $8.5 million. The Company did not recognize a change in the estimated fair value of its contingent consideration during the nine months ended September 30, 2022. The Company recognized a $0.1 million gain on the change in fair value of its contingent consideration during the nine months ended September 30, 2021.

Unfunded Commitments

As of September 30, 2022, the Company’s unfunded commitments were as follows (in millions):

Aziyo Biologics, Inc.	$	4.0
Exeevo, Inc.		2.5
MedMinder Systems, Inc.		5.0
Trio Healthcare Ltd. Loan		1.4
Total unfunded commitments	$	12.9

Per the terms of the royalty purchase or credit agreements, unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time, and in the case of loan transactions, are subject to being advanced as long as an event of default does not exist.